Companies / AI Proteins
AI Proteins
Boston, Massachusetts, United States
The company designs and develops a new class of miniprotein medicines using artificial intelligence and lab validation.
AI Proteins, based in Boston, Massachusetts, United States, has 2 investors on file, among them Mission BioCapital and Tachyon Ventures. Its latest round on record is Series A, 18 Nov 2025.
Funding
1 round on recordRound sizes and total raised are on Fundup AI, our sister product for funding data.
Investors
2 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Portfolio page | Venture capital |
More from Mission BioCapital
52 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (90%), AI & Machine Learning (4%), E-commerce & Marketplaces (2%).
See Mission BioCapital's full profile · Who invests alongside it
More from Tachyon Ventures
15 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (100%).
See Tachyon Ventures' full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get AI Proteins and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Mission BioCapital adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/aiproteins.bio/investors
# also
GET /v1/companies/aiproteins.bio
GET /v1/companies/aiproteins.bio/news